FR2847817B1 - Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires - Google Patents

Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires

Info

Publication number
FR2847817B1
FR2847817B1 FR0214980A FR0214980A FR2847817B1 FR 2847817 B1 FR2847817 B1 FR 2847817B1 FR 0214980 A FR0214980 A FR 0214980A FR 0214980 A FR0214980 A FR 0214980A FR 2847817 B1 FR2847817 B1 FR 2847817B1
Authority
FR
France
Prior art keywords
treatment
histone deacetylase
deacetylase inhibitor
muscle dystrophies
dystrophies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0214980A
Other languages
English (en)
Other versions
FR2847817A1 (fr
Inventor
La Porte Sabine De
Maurice Israel
Vincent Voisin
Hafedh Haddad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0214980A priority Critical patent/FR2847817B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PCT/FR2003/003530 priority patent/WO2004050076A1/fr
Priority to CA2507450A priority patent/CA2507450C/fr
Priority to EP03789530A priority patent/EP1565175A1/fr
Priority to AU2003294110A priority patent/AU2003294110A1/en
Priority to US10/536,417 priority patent/US20060148684A1/en
Publication of FR2847817A1 publication Critical patent/FR2847817A1/fr
Application granted granted Critical
Publication of FR2847817B1 publication Critical patent/FR2847817B1/fr
Priority to US12/006,497 priority patent/US20080160108A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
FR0214980A 2002-11-28 2002-11-28 Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires Expired - Fee Related FR2847817B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0214980A FR2847817B1 (fr) 2002-11-28 2002-11-28 Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
CA2507450A CA2507450C (fr) 2002-11-28 2003-11-28 Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
EP03789530A EP1565175A1 (fr) 2002-11-28 2003-11-28 Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
AU2003294110A AU2003294110A1 (en) 2002-11-28 2003-11-28 Use of a histone deacetylase inhibitor for treating muscular dystrophies
PCT/FR2003/003530 WO2004050076A1 (fr) 2002-11-28 2003-11-28 Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
US10/536,417 US20060148684A1 (en) 2002-11-28 2003-11-28 Use of a histone deacetylase inhibitor for treating muscular dystrophies
US12/006,497 US20080160108A1 (en) 2002-11-28 2008-01-03 Method of treating muscular dystrophies with an inhibitor of histone deacetylase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214980A FR2847817B1 (fr) 2002-11-28 2002-11-28 Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires

Publications (2)

Publication Number Publication Date
FR2847817A1 FR2847817A1 (fr) 2004-06-04
FR2847817B1 true FR2847817B1 (fr) 2006-11-10

Family

ID=32309803

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0214980A Expired - Fee Related FR2847817B1 (fr) 2002-11-28 2002-11-28 Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires

Country Status (6)

Country Link
US (2) US20060148684A1 (fr)
EP (1) EP1565175A1 (fr)
AU (1) AU2003294110A1 (fr)
CA (1) CA2507450C (fr)
FR (1) FR2847817B1 (fr)
WO (1) WO2004050076A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029152A2 (fr) * 2006-09-08 2008-03-13 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
US20120010176A1 (en) * 2008-11-12 2012-01-12 Khurana Tejvir S Utrophin promoter activity upregulation for the treatment of muscular dystrophy
WO2010086040A1 (fr) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines pour traitement de la myopathie de duchenne
US20140147434A1 (en) * 2011-05-06 2014-05-29 Ecole Polytechnique Federale De Lausanne (Epfl) NCoR1 is a Physiological Modulator of Muscle Mass and Oxidative Function
CN107007580A (zh) * 2012-02-03 2017-08-04 意大发马克股份公司 用于治疗肌肉萎缩症的化合物
FR2993461B1 (fr) * 2012-07-19 2014-08-08 Genethon Utilisation de composes modifiant l'epigenome pour le traitement des maladies genetiques musculaires liees a une anomalie de conformation proteique
WO2023278684A1 (fr) * 2021-06-30 2023-01-05 Massachusetts Institute Of Technology Compositions et méthodes de traitement de la dysferlinopathie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439939A (en) * 1992-03-17 1995-08-08 Children's Hospital Medical Center Of Northern California Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
CZ20011342A3 (cs) * 1998-10-13 2001-09-12 Fujisawa Pharmaceutical Co., Ltd. Cyklické tetrapeptidy
AU3757600A (en) * 1999-03-19 2000-10-09 Vertex Pharmaceuticals Incorporated Oral low dose butyrate compositions
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
US6376508B1 (en) * 2000-12-13 2002-04-23 Academia Sinica Treatments for spinal muscular atrophy
US6720445B2 (en) * 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
EP2082737B1 (fr) * 2002-03-04 2014-12-31 Merck HDAC Research, LLC Procédés d'induction de différentiation de terminal

Also Published As

Publication number Publication date
CA2507450C (fr) 2014-07-08
US20080160108A1 (en) 2008-07-03
AU2003294110A1 (en) 2004-06-23
CA2507450A1 (fr) 2004-06-17
FR2847817A1 (fr) 2004-06-04
US20060148684A1 (en) 2006-07-06
WO2004050076A1 (fr) 2004-06-17
EP1565175A1 (fr) 2005-08-24

Similar Documents

Publication Publication Date Title
IL164007A0 (en) New inhibitors of histone deacetylase
FR22C1033I1 (fr) Utilisation de dihydroimidazolones pour le traitement des chiens
IL164659A0 (en) Inhibitors of histone deacetylase
EE200200062A (et) Monoaminoksüdaasi inhibiitorite kasutamine ravimite valmistamiseks rasvumuse raviks
CY2015053I2 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
IL164002A0 (en) Sulfonyl-derivatives as novel inhibitors of histone deacetylase
HK1080465A1 (zh) 作為組蛋白脫乙酰酶新穎抑制劑的磺酰基氨基衍生物
EG25655A (en) Benzamide derivatives useful as histone deacetylase inhibitors
PL349900A1 (en) Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
NO20014047D0 (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
PL374970A1 (en) Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
AU2003219595A8 (en) Alpha,beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
HUP0402370A3 (en) Pharmaceutical compositions containing cyclooxigenase-2 inhibitor and histone deacetylase inhibitor combination
GB0226855D0 (en) Histone deacetylase inhibitors
AU2003255413A8 (en) Use of lck inhibitor for treatment of immunologic diseases
EP1560583A4 (fr) Inhibiteurs de l'histone desacetylase pour le traitement de maladies et de troubles oculaires, neovasculaires ou oedemateux
FR2847817B1 (fr) Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
FR2848844B1 (fr) Utilisation d'un alkylether d'hydroxystilbene pour le traitement des peaux seches
NO20032183L (no) Histon-deacetylase-inhibitor og anvendelse derav
SI1569634T1 (sl) Uporaba PPAR-alfa agonista in metformina za zdravljenje obezitete
IL147363A0 (en) Ppar delta inhibitor for the treatment of cardiovascular diseases
FR2834887B1 (fr) Utilisation d'un extrait d'artemia pour le traitement des peaux agees
ID20794A (id) Penggunaan inhibitor penukar natrium-hidrogen untuk pembuatan sediaan farmasi untuk pengobatan gangguan yang disebabkan oleh protozoa
GB0202187D0 (en) "Inhibitors"
TWI346661B (en) Inhibitors of histone deacetylase

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 14

ST Notification of lapse

Effective date: 20170731